Navigation Links
Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
Date:7/23/2008

Company Focused on IND-Enabling Work with Protein Therapeutics that

Modulate Alternative Pathway of Complement System

CAMBRIDGE, Mass., July 23 /PRNewswire/ -- Taligen Therapeutics Inc. today announced it has initiated a corporate growth plan with the appointment of Abbie Celniker, Ph.D., as chief executive officer and the establishment of its headquarters in Cambridge, Mass. Dr. Celniker succeeds Woodruff Emlen, M.D., a co-founder of the company who remains president.

Under Dr. Celniker's leadership, Taligen intends to build its late-stage research and development operations in Cambridge while maintaining in Denver its early discovery activities that are closely aligned with an international complement biology research network organized by Michael Holers, M.D., one of the company's founders.

"Abbie's expertise will be critical to the acceleration of our efforts to develop protein therapeutics that are designed to modulate the alternative pathway of the complement system," said Dr. Emlen. "We are currently focused on IND-enabling work with our therapeutic candidates. Moreover, we have advanced our programs to the point where Abbie's significant experience in devising and implementing strategies and building infrastructure for the development of biologics will enable us to realize the potential of our expertise in complement biology."

Prior to joining Taligen, Dr. Celniker was global head of Novartis Biologics, where she built and oversaw Novartis' strategy and infrastructure for the late-stage discovery and development of protein therapeutics. Before this, she held senior research and development leadership positions with Millennium Pharmaceuticals, Wyeth BioPharma (Genetics Institute) and Genentech. Dr. Celniker earned a Ph.D. in molecular biology from the University of Arizona and a B.A. in biology from the University of California, San Diego.

"We are excited to have attracted someone of Abbie's caliber to Taligen at a time the company is moving rapidly toward the clinical development stage," said Tim Mills, Ph.D., Taligen's chairman and a managing director with Sanderling Ventures. "I look forward to working with her as we implement our corporate growth plan to build a company focused on the development of a pipeline of protein therapeutics intended for the treatment of diseases where complement dysregulation is implicated."

In January Taligen closed the first tranche of a $65 million Series B financing led by Alta Partners and Clarus Ventures with participation from existing investors Sanderling Ventures, Tango and High Country Venture. The financing is expected to enable Taligen to implement its growth plan and advance multiple product candidates to the proof-of-concept stage.

"I am thrilled to join and lead the Taligen team," said Dr. Celniker. "The complement system is emerging as a critical area for drug development. Taligen's founders discovered and validated the importance of the alternative pathway as an amplification loop in the inflammation process. Based on this expertise, the company has designed protein therapeutics that are intended for the treatment of a wide range of orphan and large indications. These programs are cutting-edge and should be very appealing to prospective corporate partners. With the company's expertise, protein therapeutic development candidates and strong financial backing, Taligen is well-positioned to implement its corporate growth plan."

About Taligen Therapeutics

Taligen Therapeutics is focused on the discovery and development of novel protein therapeutics that are designed to modulate the alternative pathway of the complement system to treat a wide range of inflammatory conditions and diseases. The company's lead therapeutic candidates are monoclonal antibodies and recombinant fusion proteins that target key factors in the alternative pathway, which Taligen's founders have validated as an important amplification loop in the inflammation process. Taligen's headquarters and late-stage research and development operations are located in Cambridge, Mass. The company also maintains a drug discovery operation in Denver that is closely aligned with an international complement biology research network organized by Michael Holers, M.D., one of the company's founders. For more information, visit http://www.taligentherapeutics.com.

This press release contains forward-looking statements that involve risks and uncertainties, including statements relating to development of the Company's product candidates and potential advantages of the Company's technology and product candidates. Actual results could differ materially from those projected and the Company cautions readers not to place undue reliance on the forward-looking statements contained in this release.

Media Contacts:

David Schull or Robert Flamm, Ph.D.

Russo Partners

(212) 845-4271

david.schull@russopartnersllc.com

robert.flamm@russopartnersllc.com


'/>"/>
SOURCE Taligen Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
2. Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders
3. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
4. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
5. Velcura Therapeutics, Inc. Adds William Brinkerhoff to its Board of Directors
6. PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124
7. Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
8. Nile Therapeutics Announces Dosing in Phase IIa Study of CD-NP in Heart Failure Patients
9. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
10. Silence Therapeutics Announces Board Changes
11. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... GAITHERSBURG, Md. , Aug. 7, 2017 /PRNewswire/ ... for healthcare member acquisition, retention, and engagement, announced ... Director of Strategy and Product Development, effective as ... strategic consulting and technology implementation strategy for our ... years of experience in consulting and business analytics ...
(Date:8/7/2017)... 7, 2017  Endo International plc (NASDAQ: ... resolve virtually all known U.S. mesh product liability claims ... the known remaining U.S. claims at reasonable values. Under ... the fourth quarter of 2017 and continuing through the ... quarter 2017 results, the Company intends to increase its ...
(Date:8/2/2017)... , Aug. 2, 2017 Fenita ... Who as a Pinnacle Lifetime Professional in the ... Account Manager at Turing Pharmaceuticals, AG. Her skills ... and relationship building.                ... than 25 years of experience as a highly ...
Breaking Medicine Technology:
(Date:8/17/2017)... ... August 17, 2017 , ... CareAcademy, ... that it has raised $1.675 M in seed funding to further expand its ... and Techstars Venture Capital Fund are the company’s primary investors. , ...
(Date:8/17/2017)... ... , ... Centrifugation is more than just spinning. Like a car in our ... do without. And just like a car, there are a few points to consider ... will learn about the most important safety aspects while using a centrifuge, as well ...
(Date:8/16/2017)... ... , ... The next Patient Care Academy at Kalamazoo Valley Community College begins ... the seven-week long Patient Care Academy are eligible to take the State of Michigan ... CNA in Kalamazoo is $24,428.* , As a CNA, one is equipped for employment ...
(Date:8/16/2017)... ... August 16, 2017 , ... The Data Council, the leading ... was acquired by Advantage Solutions. The Data Council’s IX-ONE platform is the ... industry’s leading suppliers, brokers, distributors and retailers. The Data Council will become a ...
(Date:8/16/2017)... ... August 16, 2017 , ... QualDerm Partners , ... development, today announced Cumberland Skin Surgery and Dermatology has joined the ... offices in both Hermitage and Lebanon, Tennessee, provides comprehensive general dermatology and skin ...
Breaking Medicine News(10 mins):